Literature DB >> 7531421

Successful application of the Norwood procedure for infants without hypoplastic left heart syndrome.

K R Kanter1, B E Miller, A G Cuadrado, R N Vincent.   

Abstract

Although the first-stage Norwood procedure mostly has been used for hypoplastic left heart syndrome, there are other anomalies in which the Norwood procedure can be applied. Since 1991, 18 newborns without hypoplastic left heart syndrome underwent a first-stage Norwood procedure. All had a hypoplastic aortic annulus, ascending aorta, and transverse aorta. Ten had normally related great arteries: aortic atresia or aortic stenosis with inadequate left ventricle in 4, mitral atresia or stenosis in 4, and interrupted aortic arch in 2. The 8 others had double-outlet right ventricle with mitral atresia or complete transposition with a hypoplastic right ventricle. Age ranged from 2 to 77 days (median, 6 days) and weight from 2.4 to 4.4 kg (mean, 3.0 kg). The patients with interrupted aortic arch simultaneously underwent primary repair of the interruption. There were 17 hospital survivors (94%). There have been no late deaths in follow-up from 4 to 30 months (mean, 15.5 months). Thirteen children have had subsequent creation of a bidirectional Glenn shunt with takedown of the original systemic to pulmonary shunt. The 2 with interrupted aortic arch underwent a Rastelli-type biventricular repair. These results show that the Norwood procedure can be applied to infants without hypoplastic left heart syndrome who have hypoplastic aortas and excessive pulmonary blood flow with very low mortality and excellent palliation.

Entities:  

Mesh:

Year:  1995        PMID: 7531421     DOI: 10.1016/0003-4975(94)00944-3

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  3 in total

1.  Surgical strategy for severe aortic hypoplasia and aortic stenosis with ventricular septal defect and normal left ventricle.

Authors:  Takahiro Tomoyasu; Norihiko Oka; Takashi Miyamoto; Tadashi Kitamura; Keiichi Itatani; Nobuyuki Inoue; Masahiro Ishii; Kagami Miyaji
Journal:  Pediatr Cardiol       Date:  2012-12-19       Impact factor: 1.655

Review 2.  Accepting risk in clinical research: is the gene therapy field becoming too risk-averse?

Authors:  Claire T Deakin; Ian E Alexander; Ian Kerridge
Journal:  Mol Ther       Date:  2009-09-22       Impact factor: 11.454

3.  Outcomes of the modified norwood procedure: hypoplastic left heart syndrome versus other single-ventricle malformations.

Authors:  Randall S Fortuna; Mark Ruzmetov; Dale M Geiss
Journal:  Pediatr Cardiol       Date:  2013-08-08       Impact factor: 1.655

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.